Our technology
National Cancer Institute evaluates Allera data for "Best Case Series"Tampa, FL (September 2008) – Allera Health Products, in collaboration with the Tampa Bay Research Institute (TBRI) has submitted patient data to the National Cancer Institute (NCI) Best Case Series Program for consideration. Allera and TBRI have become aware of several cancer patients that appear to have shown positive response to Allera’s Proligna pinecone extract. In both instances, tumors remain in check for an extended period of time with minimal or no additional cancer therapy administered. In all instances, patients were first treated with the very best standard of care (surgery, radiation, chemotherapy), and only then were they evaluated for response to Proligna pinecone extract.
“These early results that are not predictive of a widespread response in all cancer patients,” says Frank Tufaro, Ph.D., President and CEO of Allera Health Products. “The data are somewhat surprising, however, given that these patients had exhausted conventional therapies and had a very poor prognosis. The evaluation of our data by physicians at the NCI is an important step in achieving our goal to uncover the true potential of our compound and to determine whether Proligna can be added to the arsenal of weapons for fighting cancer”.
The National Cancer Institute (NCI) is committed to finding innovative, promising treatments for people with cancer. The NCI’s Office of Cancer Complementary and Alternative Medicine (OCCAM) coordinates the Institute’s research program in complementary and alternative medicine (CAM). Since 1991, the NCI has had a process for evaluating data from CAM practitioners that involves the same rigorous scientific methods employed in evaluating treatment responses with conventional medicine. This process, called the NCI Best Case Series (BCS) Program, provides an independent review of medical records and medical imaging from patients treated with unconventional cancer therapies. Through this program, staff from the OCCAM work with CAM practitioners to identify appropriate, well-documented cases. The primary goal of this program is to obtain and review sufficient information to determine if NCI-initiated research on a specific intervention is warranted.
